About Exatecan Derivative for ADC
We have established ourselves as a renowned manufacturer, exporter and supplier ofDX-8951 derivative. Our skilled professionals formulate these compounds by making use of various ingredients and chemicals available in the market. We formulate these drugs in our using latest equipment therefore these medicines have longer shelf life and are very effective8-Quinolinesulfonyl chlorideis available in various specifications to meet our clients demands.
Other details:
Product name:8-Quinolinesulfonyl chloride
Synonyms:8-Chlorosulfonyl-1-benzazine, 8-Quinolylsulfonyl chloride, 8-QUINOLINESULFONYL CHLORIDE, Quinoline-8-sulfonyl chloride, Quinoline-8-sulphonyl chloride, Q1506_ALDRICH, Quinoline-8-sulfonic acid chloride, 22695_FLUKA, EINECS 242-515-5, NSC 91506, ALBB-006398, NSC91506, BRN 0156347, CC 04303, FS000331, LS-142148, 5-22-07-00567 (Beilstein Handbook Reference)
CAS NO.: 18704-37-5
Molecular Formula:C9H6ClNO2S
Molecular Weight:227.67
Preserve in well-closed containers
Precision in Pharmaceutical ApplicationsExatecan Derivative is highly valued for its use in the ADC field, where precise targeting and efficacy in anti-cancer therapies are required. With a high purity level of 99%, this compound ensures consistency in research and pharmaceutical production. Its reliable performance is pivotal for advanced therapeutic innovation.
Quality Assurance and SourcingSourced from China, Exatecan Derivative undergoes stringent quality control processes, verifying its molecular specifications and purity. Trusted by exporters, distributors, and manufacturers worldwide, it guarantees optimal results in pharmaceutical synthesis and product formulation.
FAQs of Exatecan Derivative for ADC:
Q: How is Exatecan Derivative commonly used in the pharmaceutical industry?
A: Exatecan Derivative serves as a crucial component in the formation of Antibody-Drug Conjugates (ADCs), which are advanced therapies aimed at delivering cytotoxic agents directly to cancer cells, thereby minimizing damage to healthy tissue.
Q: What is the typical process for incorporating Exatecan Derivative into ADC development?
A: The process involves conjugating Exatecan Derivative to a monoclonal antibody through a linker, forming an ADC. This allows for selective delivery and release of the drug in targeted cancer cells during clinical or preclinical work.
Q: When is Exatecan Derivative recommended for use in drug discovery?
A: It is most commonly recommended at stages where targeted cytotoxicity and high specificity are needed for oncology drug research and preclinical testing of Antibody-Drug Conjugates.
Q: Where can one procure Exatecan Derivative with guaranteed quality?
A: This derivative is supplied by reputable manufacturers, distributors, and exporters in China, ensuring high purity and quality standards for global supply to research and pharmaceutical organizations.
Q: What benefits does Exatecan Derivative provide in ADC applications?
A: Using Exatecan Derivative enables the design of medicine with targeted anticancer activity, enhancing therapeutic index while lowering systemic toxicity, an essential benefit in next-generation oncology treatments.
Q: How should Exatecan Derivative powder be stored for optimal stability?
A: It should be kept in a tightly sealed container, stored in a cool, dry environment, and protected from moisture and direct sunlight to maintain its purity and effectiveness during handling and storage.